TrialLeukemia2022

Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.

Edoardo Pennesi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.